A multi-institutional retrospective study of osimertinib for elderly patients with previously untreated advanced non-small cell lung cancer harboring EGFR mutations (HOT2002)

A multi-institutional retrospective study of osimertinib for elderly patients with previously untreated advanced non-small cell lung cancer harboring EGFR mutations (HOT2002) - HOT2002

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044101

Enrollment

100

Registered

2021-05-04

Start date

2020-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced/Relapsed non-small cell lung cancer 2.Patients who received first-line osimertinib between August 2018 and December 20119

Exclusion criteria

Exclusion criteria: Patients who had received other EGFR-TKIs before receiving osimertinib were excluded.

Design outcomes

Primary

Measure	Time frame
the proportion of patients who were progression-free survival at 1 year (1-year PFS)	—

Secondary

Measure	Time frame
safety profile, objective response rate (ORR), disease control rate (DCR), PFS, and overall survival (OS)	—

Countries

Japan

Contacts

Public ContactGaku Yamamoto

Hokkaido University Graduate school of Medicine Department Respiratory Medicine, Faculty of Medicine

gaku.yamamoto0306@pop.med.hokudai.ac.jp011-706-5911

Outcome results